GLP-1 for African American Patients: Health Disparities & Access

Introduction

African American adults have higher rates of obesity (48.2% versus 41.4% in non-Hispanic white adults per CDC 2023), type 2 diabetes (12.1% versus 7.4%), hypertension (56% versus 48%), and chronic kidney disease (about 16% versus 13%). The cardiovascular event rate is roughly 30 to 50% higher.

These disparities are partly driven by social determinants of health (access to care, food environment, environmental stressors) and partly by biological differences (kidney function patterns, hypertension severity, salt sensitivity). The medical literature has documented these gaps extensively, but the access gap to newer medications has been particularly pronounced.

GLP-1 medications work well in African American patients. Trial subgroup data shows comparable weight loss and A1C reduction. The kidney protective effects from FLOW are particularly relevant given high baseline CKD rates. The challenge has been getting the medications into the hands of patients who need them.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Do GLP-1 Medications Perform in African American Patients?

Comparable weight loss and A1C reduction in trial subgroups. The medication biology does not vary meaningfully by race.

Quick Answer: African American adults have 48% obesity prevalence vs 41% in non-Hispanic white adults

STEP 1 enrolled about 5.8% African American participants. Weight loss was 13.7% versus 14.9% overall, statistically similar. STEP 2 in patients with type 2 diabetes had higher African American representation and showed comparable A1C reduction.

SURMOUNT-1 enrolled about 9% African American participants. Weight loss with tirzepatide 15 mg was 18.4% versus 20.9% overall. The difference, while small, has been a focus of discussion. Possible explanations include differences in adherence, drop-out rates, and underlying metabolic factors. The medication works; the magnitude in real populations may be modestly lower.

SELECT enrolled about 4.5% African American participants. Cardiovascular event reduction was 20% overall, with consistent benefit in African American participants.

FLOW (Perkovic et al. 2024 NEJM) is particularly important. It showed semaglutide reduced the composite of kidney failure, kidney death, and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease. Given that African American patients have higher CKD rates (about 16% vs 13% in non-Hispanic white adults), this benefit is highly relevant.

What About Kidney Disease Specifically?

African American patients have 3 to 4 times higher rates of end-stage kidney disease than non-Hispanic white patients. The APOL1 genetic variants associated with kidney disease are common in patients with African ancestry.

The FLOW trial enrolled patients with diabetes and CKD. Median age was 66, eGFR ranged from 25 to 75, and many had albuminuria. The 24% reduction in the composite kidney/CV endpoint was driven primarily by slowing progression of kidney disease.

For African American patients with diabetes and any degree of kidney dysfunction, the case for semaglutide therapy is strong. The kidney protection is independent of glycemic control, with effects on inflammation, hemodynamics, and direct renal effects.

The 2024 KDIGO guidelines now recommend GLP-1 therapy for patients with type 2 diabetes and CKD as a kidney-protective intervention, alongside SGLT2 inhibitors. Combined SGLT2 plus GLP-1 therapy is particularly effective.

eGFR equations have been updated to remove the race coefficient that previously overestimated kidney function in Black patients. This has shifted CKD diagnosis and earlier intervention windows for African American patients.

What About Hypertension?

African American adults have 8 percentage points higher hypertension prevalence and more resistant hypertension than non-Hispanic white adults. Blood pressure responses to specific antihypertensive classes also differ.

GLP-1 medications produce blood pressure reductions averaging 5 to 8 mmHg systolic. In a population with higher baseline pressures and more resistant hypertension, this benefit is meaningful.

STEP 1 showed 6.2 mmHg systolic reduction. SELECT showed similar magnitude in the cardiovascular cohort. SURMOUNT-1 produced 7 to 8 mmHg reductions with tirzepatide 15 mg.

The mechanism is partly weight loss, partly direct vascular effects, and partly improved insulin sensitivity. For African American patients on multiple antihypertensives, GLP-1 therapy can reduce medication burden over time.

Antihypertensive class preferences differ in African American patients. Calcium channel blockers and thiazide diuretics typically produce larger blood pressure responses than ACE inhibitors or ARBs. GLP-1 effects appear to be similar across these antihypertensive backgrounds.

What About Cardiovascular Disease?

Cardiovascular mortality is about 30 to 50% higher in African American adults compared to non-Hispanic white adults. The disparities widen at younger ages.

SELECT showed 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) with semaglutide 2.4 mg in patients with established cardiovascular disease and obesity. The benefit was consistent across racial groups.

For African American patients with established cardiovascular disease, the SELECT data supports semaglutide as part of standard preventive therapy alongside statins, antiplatelets, and standard cardiovascular medications.

The 2024 CMS Medicare guidance covers semaglutide for cardiovascular risk reduction in this population. Insurance coverage has expanded as a result, partly closing the historical gap.

What Are the Specific Access Barriers?

Cost, geographic distribution of telehealth services, insurance coverage variation, and trust in the medical system.

Cost: branded GLP-1s are $1,000 to $1,400 per month list price. Without insurance coverage, this is prohibitive. African American patients have lower median household income and higher uninsured rates, so cost barriers are amplified.

Insurance coverage: coverage for obesity (Wegovy®, Zepbound®) varies by employer and state. Many Medicaid programs do not cover obesity medications. Coverage for diabetes indications is more uniform, which helps patients with type 2 diabetes but not those with obesity alone.

Compounded GLP-1s through telehealth are typically $200 to $400 per month, more accessible but not universally available. Some states have stricter rules on compounded medications.

Geographic distribution: telehealth platforms have largely solved the geographic access piece. Patients in rural areas, smaller cities, and underserved urban neighborhoods can access GLP-1 prescribing through online platforms. TrimRx is one such option.

Trust: historical and ongoing experiences of bias in medical care affect engagement with newer treatments. Transparent communication about how the medication works, what the data shows, and what side effects to expect helps build informed engagement.

Key Takeaway: FLOW (Perkovic et al. 2024 NEJM) showed semaglutide cut kidney/CV death by 24%, particularly relevant given higher CKD rates

How Do I Adapt Soul Food and Traditional African American Foods?

Traditional African American foods include both deeply nutritious options and high-fat preparations. Adaptation focuses on cooking methods and portions.

Lean protein options that fit GLP-1 patterns: baked or grilled chicken, fish (catfish, salmon, tilapia), lean beef, eggs, and beans (black-eyed peas, butter beans, navy beans). Lean ground turkey can substitute for ground beef in many traditional dishes.

Vegetable preparations: greens (collards, mustard greens, turnip greens) are nutritional powerhouses. Traditional preparation often uses ham hocks or bacon. Modify with smoked turkey wings or olive oil and garlic for less saturated fat and similar flavor.

Reduce frying: fried chicken, fried fish, fried okra are calorie-dense. Air fryer versions, oven-baked, or grilled alternatives give similar satisfaction with much less oil. Avoid daily fried preparations.

Sweet potatoes and yams in moderate portions are excellent. They are nutrient-dense and provide complex carbohydrates with fiber. Avoid heavy sugar and butter preparations.

Cornbread and biscuits in smaller portions. One small piece rather than a whole biscuit. Whole-grain variations are better than refined white flour.

Beans (red beans and rice, black-eyed peas, butter beans) are GLP-1 friendly when prepared with lean meats rather than fatty pork.

What About Sunday Dinner and Family Gatherings?

Cultural significance of food in family and church gatherings is real. The conversation around food is part of community.

Practical patterns that work: bring a healthier dish to gatherings (a vegetable side or salad), eat smaller portions of traditional dishes, focus on the social ritual rather than the food volume. Most GLP-1 patients find that the appetite suppression naturally reduces consumption at large gatherings without conscious effort.

Family conversations about health are often easier in African American families where multiple members have diabetes or hypertension. The broader health awareness creates space for discussing weight management.

Church functions, family reunions, holiday dinners all continue to center on food. Going through these on a GLP-1 is generally easier than expected. Eat what you want, eat less of it, enjoy the people.

The first major family gathering on a GLP-1 is the hardest. After that, the pattern becomes routine.

What Are the Side Effects I Should Watch for Specifically?

Standard GLP-1 side effects apply: nausea, vomiting, constipation, diarrhea. African American patients may have higher baseline rates of some gastrointestinal conditions.

Lactose intolerance is more common in African American adults (about 75% versus 25% in non-Hispanic white adults). GLP-1 nausea combined with lactose intolerance from dairy in the diet can be additive. Some patients benefit from reducing dairy during early weeks.

Hypertension monitoring is important. Blood pressure can drop substantially with weight loss, requiring antihypertensive medication adjustments. Home blood pressure monitoring during the first 3 months is valuable.

Kidney function should be monitored. Baseline creatinine and follow-up at 4 to 6 weeks. The combination of GLP-1 GI side effects and pre-existing CKD can produce AKI if hydration is inadequate.

A1C tracking even in non-diabetic patients is reasonable given higher diabetes risk. Many African American patients have undiagnosed prediabetes at baseline.

What Is the Right Monitoring Schedule?

Baseline labs include complete metabolic panel (with eGFR using race-neutral equation), A1C, lipid panel, urine albumin-to-creatinine ratio, TSH, vitamin D.

Vitamin D deficiency is very common in African American patients (about 76% have levels below 30 ng/mL). Skin pigmentation reduces vitamin D synthesis from sunlight. Reduced food intake on GLP-1 therapy can worsen deficiency. Supplementation with 2000 IU daily is often appropriate.

Follow-up at 6 to 12 weeks: BMP, A1C, blood pressure review. Adjust antihypertensive medications as needed.

Quarterly monitoring during active weight loss, then annual once stable.

A TrimRx clinician provides personalized lab and follow-up schedules based on individual risk factors.

Bottom line: Access barriers (cost, geographic distribution, telehealth) disproportionately affect African American patients

FAQ

Will the Medication Work as Well for Me as It Does in Trials?

Yes. Trial subgroup data shows comparable response across racial and ethnic groups. The medication biology does not vary meaningfully by race. Real-world results vary based on adherence, side effect management, and access.

Will My Insurance Cover a GLP-1?

Depends on the plan and indication. Coverage for type 2 diabetes is widespread. Coverage for obesity is variable. Medicaid coverage of obesity medications is limited in most states. Compounded versions through telehealth are an option when traditional insurance does not cover.

Are There Specific Risks I Should Know About?

Standard GLP-1 risks apply. Pay particular attention to hydration (kidney function), hypertension monitoring (blood pressure can drop), and vitamin D status. Cardiovascular and kidney benefits are particularly relevant.

Can I Take a GLP-1 with My Blood Pressure Medications?

Yes. ACE inhibitors, ARBs, calcium channel blockers, thiazides, and beta-blockers do not directly interact with GLP-1 medications. Doses often need adjustment downward over time as weight loss reduces blood pressure.

What If I Have Sickle Cell Disease?

GLP-1 medications are not contraindicated in sickle cell disease. The dehydration risk from GLP-1 GI side effects can theoretically trigger sickle cell crisis, so hydration is particularly important. Talk to a clinician familiar with both conditions.

How Does the FLOW Data Apply to Me?

FLOW showed semaglutide cut kidney/cardiovascular death by 24% in patients with diabetes and CKD. Given higher rates of CKD in African American patients, this evidence supports semaglutide as kidney-protective therapy. The benefit is in addition to standard CKD medications.

Where Can I Find Black Physicians Familiar with GLP-1 Therapy?

The Association of Black Cardiologists, National Medical Association, and similar professional organizations have provider directories. Telehealth platforms also have racially diverse provider rosters.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.